Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03502148 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy Study of PRV111 in Subjects With Oral Squamous Cell Carcinoma
A Phase 1 study, sponsored by Privo Technologies.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT03502148 is a Phase 1 study that has completed, run by Privo Technologies. The registered enrollment target is 10 participants.
The verdict
NCT03502148, a Phase 1 study, has completed, sponsored by Privo Technologies.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
Up to 31 subjects diagnosed with oral squamous cell carcinoma received one application of a permeation enhancer 3 treatment applications of a Cisplatin drug-loaded patch to the tumor site at each of the 4 treatment visits. These 4 treatment visits were scheduled to occur during the 3 weeks prior to the standard of care tumor resection. Funding Source: FDA OOPD
Interventions
- DRUG PRV111 (Cisplatin Transmucosal System)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2018-06-19 |
| Est. Completion | 2020-05-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03502148
The ClinicalTrials.gov registry entry for NCT03502148 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Privo Technologies, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PRV111 (Cisplatin Transmucosal System) is the first listed.
NCT03502148 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03502148 about?
NCT03502148 is a clinical study titled "Safety and Efficacy Study of PRV111 in Subjects With Oral Squamous Cell Carcinoma". Up to 31 subjects diagnosed with oral squamous cell carcinoma received one application of a permeation enhancer 3 treatment applications of a Cisplatin drug-loaded patch to the tumor site at each of the 4 treatment visits. These 4 treatment visits were scheduled to occur during the 3 weeks prior to ...
What is the current status of trial NCT03502148?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2018-06-19. Estimated completion is 2020-05-06.
What interventions are being tested in trial NCT03502148?
The interventions under investigation include: PRV111 (Cisplatin Transmucosal System) (DRUG).
Who is sponsoring clinical trial NCT03502148?
This trial is sponsored by Privo Technologies, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.